From: The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
PAH subjects 1(N = 425) | ||
---|---|---|
n | % | |
Discontinuation of index therapy regimen | 162 | 38.12 |
Switch from index therapy regimen2 | 23 | 14.20 |
Augmentation to index therapy regimen | 47 | 11.06 |
Maintenance of index therapy regimen | 224 | 52.71 |
Medication Possession Ratio (MPR) | n | mean |
Bosentan | 177 | 0.94 |
Ambrisentan | 29 | 0.94 |
Iloprost | 4 | 0.86 |
Treprostinil | 2 | 1.00 |
Epoprostenol | 0 | - |
Tadalafil (Adcirca®) | 22 | 0.94 |
Sildenafil (Revatio®) | 191 | 0.92 |